Knight Therapeutics (KHTRF) 5.4847 $KHTRF Knight

New Post Public Reply Private Reply Replies (0) Message Board

Oct 11, 2015 at 8:51 AM

Knight Therapeutics (KHTRF) 5.4847 $KHTRF

Knight Profounda U.S. Partner for Impavido
Marketwired - Mon Sep 28, 7:01AM CDT
Knight Therapeutics Inc. (TSX: GUD), through one of its wholly-owned subsidiaries, ("Knight"

announced today that it has entered into an exclusive distribution agreement with Profounda Inc. ("Profounda"

to commercialize Impavido(R)(miltefosine), an oral treatment for visceral, mucosal and cutaneous leishmaniasis, in the United States. Knight previously licensed the ex-U.S. global rights to Impavido(R) to Paladin Labs Inc. until February, 2024.
GUD.TO: 7.14 (-0.02)

Knight Takes its Dose of Medison
Marketwired - Wed Sep 09, 7:03AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight"

, a leading Canadian specialty pharmaceutical company, announced today its previously announced transaction with Medison Biotech (1995) Ltd. ("Medison"

, Israel's leading independent specialty pharmaceutical company, has closed.
GUD.TO: 7.14 (-0.02)

NEMO Ascends to New High Water Mark for Knight
Marketwired - Mon Aug 24, 7:01AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight" or the "Company"

, a leading Canadian specialty pharmaceutical company, announced today that it has received a further distribution of US$1.5 million related to its investment in Sectoral Asset Management Inc.'s New Emerging Medical Opportunities Funds II, Ltd. ("NEMO II"

following the US$13.6 million distribution announced by Knight in June 2015.
GUD.TO: 7.14 (-0.02)

Knight Reports Second Quarter 2015 Results
Marketwired - Wed Aug 12, 5:01AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight" or the "Company"

, a leading Canadian specialty pharmaceutical company, today reported its second quarter ended June 30, 2015 financial results.
GUD.TO: 7.14 (-0.02)

Knight and LFB S.A. Announce Filing of New Drug Submission for ATryn(R)
Marketwired - Thu Aug 06, 5:01PM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight" or the "Company"

, a leading Canadian specialty pharmaceutical company, and LFB S.A., a biopharmaceutical Group focused on innovative therapeutics for serious and rare diseases, today announced that Knight's New Drug Submission (NDS) has been accepted for review by Health Canada for ATryn(R) (Antithrombin (Recombinant)) for the prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients.
GUD.TO: 7.14 (-0.02)

Ember Therapeutics Raises up to $6M and Establishes Commercial Partnership with Knight Therapeutics
PR Newswire - Thu Aug 06, 3:07PM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight"

, a leading Canadian specialty pharmaceutical company and Ember Therapeutics, Inc. ("Ember"

, a privately held, New York-based biotechnology company developing targeted therapies for osteoarthritis, kidney fibrosis and other indications using Bone Morphogenetic Protein (BMP)-7 announced today that Knight has extended a secured loan of US$1 million and may provide additional equity commitments to Ember valued up to US$5 million. In addition, Knight has entered into an exclusive distribution agreement with Ember, a cutting-edge U.S.-based biopharmaceutical company, to commercialize its promising Bone Morphogenetic Protein-7 ("BMP-7"

pipeline in Canada and select international markets.
GUD.TO: 7.14 (-0.02)

Knight Sparks Ember Partnership
Marketwired - Wed Aug 05, 4:01PM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight"

, a leading Canadian specialty pharmaceutical company and Ember Therapeutics, Inc. ("Ember"

, a privately held, New York-based biotechnology company developing targeted therapies for osteoarthritis, kidney fibrosis and other indications using Bone Morphogenetic Protein-7 ("BMP-7"

, announced today that Knight has extended a secured loan of US$1 million and may provide additional equity commitments of up to US$5 million. In addition, Knight has entered into an exclusive distribution agreement with Ember, a cutting-edge U.S.-based biopharmaceutical company, to commercialize its promising BMP-7 pipeline in Canada, Israel, Russia and sub-Saharan Africa.
GUD.TO: 7.14 (-0.02), SYK: 97.75 (+0.40)

Knight Therapeutics Announces an Exclusive Distribution Agreement for AzaSite(R) in Canada
Marketwired - Fri Jul 24, 5:00PM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight"

a leading Canadian specialty pharmaceutical company, today announced the signing of an exclusive agreement with Akorn, Inc. ("Akorn"

of Lake Forest, Ill., for the exclusive distribution of AzaSite(R) in Canadian markets. Under the terms of the agreement with Akorn, Knight will handle all regulatory and commercial activities for AzaSite(R) in Canada.
AKRX: 29.90 (+0.39), GUD.TO: 7.14 (-0.02)

Alimera Sciences enters into Canadian distribution agreement for ILUVIEN with Knight Therapeutics
M2 - Wed Jul 22, 5:08AM CDT
Pharmaceutical company Alimera Sciences (NasdaqGM:ALIM) revealed on Tuesday the launch of an exclusive agreement for the distribution in Canada of its sustained release intravitreal implant for the treatment of diabetic macular edema, ILUVIEN.
ALIM: 2.61 (+0.04)

Alimera Sciences Signs Knight Therapeutics as Exclusive ILUVIEN(R) Distributor for Canada
Marketwired - Tue Jul 21, 7:02AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"

, a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has signed an exclusive agreement with Knight Therapeutics Inc. (TSX: GUD) ("Knight"

, a leading Canadian specialty pharmaceutical company, for the distribution in Canada of ILUVIEN(R), Alimera's sustained release intravitreal implant for the treatment of diabetic macular edema. Under the terms of this agreement, Knight will also handle all regulatory and commercial activities for ILUVIEN in Canada. ILUVIEN currently is not approved for sale in Canada.
ALIM: 2.61 (+0.04), GUD.TO: 7.14 (-0.02)

Alimera Sciences Signs Knight Therapeutics As Exclusive ILUVIEN® Distributor For Canada
PR Newswire - Tue Jul 21, 6:30AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"

, a leading Canadian specialty pharmaceutical company, for the distribution in Canada of ILUVIEN®, Alimera's sustained release intravitreal implant for the treatment of diabetic macular edema. Under the terms of this agreement, Knight will also handle all regulatory and commercial activities for ILUVIEN in Canada. ILUVIEN currently is not approved for sale in Canada.
ALIM: 2.61 (+0.04), GUD.TO: 7.14 (-0.02)

Knight Lends a Hand to a New Debt Fund
Marketwired - Thu Jul 09, 4:01PM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight"

, a leading Canadian specialty pharmaceutical company, announced today that it has invested in the Bloom Burton Healthcare Lending Trust (the "Trust"

managed by Stratigis Capital Advisors Inc. Knight subscribed for $500,000 Trust units as part of a $15.9 million private placement. The Trust will use the proceeds to invest in debt and debt-like securities of emerging commercial-stage public and private Canadian healthcare companies that have been overlooked by traditional lenders.
GUD.TO: 7.14 (-0.02)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CJ BIO's Bold Steps for Sustainable Animal Nutrition

Breaking New Ground in Animal Nutrition Picture this: industry big wigs and farmers alike, all rubbing elbows at EuroTier 2026, the grand meeting ground for animal nutrition's future. This is where CJ BIO is flexing its muscles, not by just tossing ingredients into the mix, but by revolutionizing them under the banner "Feed Intelligence for Sustainable Performance." Now,...

Context Labs Unveils AI Distillery for Enterprises

Rethinking AI with Sovereignty in Mind A bouquet of tech buzzwords lands on every investor's doorstep with the unveiling of Context Labs' latest contraption. We’re talking about the AI Distillery™, which promises enterprises a way to run sovereign AI systems by keeping data in-house. Now, if you’re nodding along to the buzz, let's cut through the clutter....

Smart Salary Moves for S Corp Owners: Riggs Unpacks Insights

Decoding the S Corp Salary Dance How much salary should the savvy owners of S corporations draw? It ain't a simple task or one-size-fits-all deal, folks. David Riggs spills the beans on HelloNation, sharing insights on this complex tango between drawing wages and raking in shareholder distributions. In the end, it’s about playing by the IRS rules—or risking a penalty...

Dutch Bros Pours Holiday Cheer with New Festive Menu

New Festive Offerings from Dutch Bros Kicking off the holiday season with a splash of vibrant flavors, Dutch Bros is shaking up the menu with some fresh, festive entries. Two new drink concoctions hit the stage alongside a themed delectable treat, and for those traditionalists, perennial favorites make a triumphant return. Dutch Bros Expands Its Vibrant Lineup It's not...

UBCF Strikes Big in Times Square with New Billboards

From the Shadows to the Spotlight Ever seen someone step up to the plate and knock it out of the park? That's what the United Breast Cancer Foundation (UBCF) is doing by plastering their mission right across Times Square. Talk about grabbing the bull by the horns, eh? With not one, but two billboards now gracing one of the globe's most iconic public spaces, they've...

Why Accurate HVAC Load Calculations Matter

Beyond Square Footage: Critical HVAC Considerations When it comes to heating and cooling your home, simply considering its square footage is like trying to predict the weather with nothing but a coin flip. Bob Schmid, an HVAC guru from Ocean View, NJ, pulls back the curtain on why the details really matter in determining the most efficient and effective HVAC setup for any...

Shenzhen's Theme Song Unveils APEC 2026 Vision

A Harmonious Prelude to APEC China 2026 Ever experienced an anthem that captures a city's pulse? That's what Shenzhen's latest creation aims for as it gears up for APEC China 2026. The Publicity Department of the CPC Shenzhen Municipal Committee, alongside Shenzhen Media Group, has crafted something more than just a tune. This is 'Meet You Where Wonders Bloom', a melody...

SKYWORTH Solar's Solavita: Energizing Global Microgrids

Aiming for Global Reach with Solavita Usually, when a company flings a new brand into the arena, you're looking at a whole bunch of promises and probably a fat folder of paperwork you don't want to read. But when SKYWORTH Solar dishes out Solavita as its new ace in the smart microgrid game, you reckon there's a bit of serious starch in the collar. Harnessing Worldwide...

Wulcea Pioneers Safety in Smart Heated Apparel

Tech Behind the Warmth and Safety You ever turn on a heated jacket and wonder if it'll keep you safe as much as warm? That's the scene with Wulcea, a brand diving headfirst into the smart heated clothing market. People are waking up to what’s inside these technological coats, not just how they feel on a frosty walk. It’s the kind of scenario where safety meets...

China-Malaysia Youth Dialogue: Tackling Ocean Challenges

Building Bridges Across Waters These aren't the afternoons of trading stocks, folks—this one dives into the depths of the ocean and the tumultuous waters between China and Malaysia. October 30 saw the China-Malaysia Youth Ocean Dialogue take place at the China Media Group Sanya Studio, bringing together some sharp minds from both nations, tackling something that goes...